Adrulipase found safe but may miss main efficacy goal in CF trial
A new adrulipase formulation for people with cystic fibrosis (CF), designed as a treatment for exocrine pancreatic insufficiency or EPI — when the small intestine is unable to fully digest food due to problems with digestive enzymes from the pancreas — was deemed safe and well tolerated in a…